2023年4月22日

補充療法GmbH (CTx) -生物技術公司開發新的療法臨床前階段complement-mediated疾病——宣布完成€7200萬係列融資。這一輪融資是由Gimv Belgian-based私人股本和風險資本基金共同Forbion作為現有投資者,進一步加入了BioGeneration企業(BGV) Panakes夥伴,劍橋創新資本(CIC),陰間的企業和Seroba生命科學。CTx是曼徹斯特大學的分離出來的初始資金BGV隨後在2021年和2022年2月在種子資金籌集了500萬€Forbion和BGV。一輪融資,CTx擁有先進CTx001通過臨床前概念和獲得了一個創新的護照從藥物和保健產品監管署(MHRA),並啟動non-interventional自然曆史研究在英國(我獲得)。我獲得的研究結果將有助於支持CTx001臨床發展規劃。最近FDA批準的第一個intravitreal治療遺傳算法GA患者來說是一個重要的裏程碑和視網膜社區,進一步驗證補充係統的關鍵作用在遺傳算法的開發和發展同時強調針對補充作為治療策略的重要性。小說和CTx001基因治療的作用機製有潛力提供卓越的功效比競爭藥物和降低治療患者經過一晚的負擔的方法,從而改變治療景觀。除了資金,邁克爾Vlemmix (Gimv),搶劫樵夫(Panakes),安妮•霍根(CIC)和羅傑·富蘭克林(陰間的合資企業)將加入董事會新成員。資金將用於:新的一輪融資,CTx將繼續發展和完成一個階段Ib臨床證明其鉛產品CTx001的概念。和CTx001高度創新AAV基因療法治療Geograpic萎縮(GA)二級幹年齡相關性黃斑變性(dry-AMD)。 Plus the proceeds from this financing will be deployed to grow its laboratory-based activities in Stevenage (UK), evaluate CTx’s pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform. KEY QUOTES: “With a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of GA through to the clinic. The support of this broad syndicate enables us to generate additional data demonstrating CTx001’s unique and differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.” — Dr. Rafiq Hasan, CEO and Managing Director at Complement Therapeutics GmbH “We are proud to have been able to build this syndicate and look forward to supporting Complement Therapeutics in its next phase of development. The company and its team combine deep research insights, strong industry background, and a robust understanding of complement-mediated conditions, in particular GA secondary to AMD. These strengths, coupled with a focus on addressing the significant unmet need in GA, positions the company to change the way the disease is addressed and potentially achieve meaningful therapeutic impact.” — Michaël Vlemmix, Principal in the Life Sciences platform of Gimv “We are delighted with the rapid progress made by Complement Therapeutics in the last 12 months. Patients impacted by complement-mediated diseases often have to cope with debilitating symptoms throughout their lifetime and this can lead to a significant burden on them and their families. We look forward to supporting the Company as it drives forward a pipeline of novel assets addressing these unmet needs in complement-mediated diseases.” — Dr. Dmitrij Hristodorov, Partner, Forbion Trending on Pulse 2.0